# DESCRIPTION

## FIELD OF INVENTION

- introduce oligonucleotides and in vitro cell based assays

## BACKGROUND

- limitations of in vitro toxicity assays

## SUMMARY OF THE INVENTION

- introduce in vitro toxicity assays
- describe primary mammalian hepatocytes assay
- identify molecular markers of toxicity
- correlate with in vivo toxicity profile
- provide in vitro screen for in vivo toxicity
- describe method for predicting in vivo toxicity

## DETAILED DESCRIPTION OF THE INVENTION

### Prediction of In Vivo Toxicity

- predict in vivo toxicity of oligonucleotide

### Primary Mammalian Hepatocyte Cells

- describe primary mammalian hepatocyte cells
- identify biomarkers for in vivo toxicity

### Administering the Oligonucleotideâ€”Gymnotic Delivery (Gymnosis)

- describe gymnotic delivery of oligonucleotide
- measure biomarkers after gymnotic delivery

### Control Data/Reference Values

- determine control data for biomarkers

### (Determination of) Hepatotoxicity

- define hepatotoxicity biomarkers
- describe in vivo hepatotoxicity determination
- outline screening library of variants
- summarize stereodefined oligonucleotides
- describe method of reducing toxicity

### Parent Oligonucleotide

- describe parent oligonucleotide

### Library of Variants

- create library of stereodefined oligonucleotide variants
- describe stereodefined phosphorothioate internucleoside linkages
- outline creation of child oligonucleotides
- summarize stereodefined phosphorothioate linkages

### Stereodefined Oligonucleotide Embodiments:

- outline stereodefined oligonucleotide variants
- describe method of reducing toxicity

### Primary Hepatocytes Assay Example:

- describe cell culture conditions

## Definitions

### Oligonucleotide

- define oligonucleotide
- describe characteristics of oligonucleotides

### Antisense Oligonucleotides (ASOs)

- define antisense oligonucleotides

### Modified Internucleoside Linkages

- describe modified internucleoside linkages

### Modulation of Expression

- define modulation of expression

### Modified Oligonucleotides

- introduce modified oligonucleotides
- describe phosphorothioate internucleoside linkages
- discuss high affinity modified nucleosides
- summarize sugar modifications
- define modified oligonucleotides
- specify embodiments
- define modified oligonucleotides
- describe biradical structures
- specify substituent groups
- provide examples of bicyclic nucleotides
- describe LNA structure and stereochemistry
- define modified oligonucleotides
- describe gapmer structure
- outline gapmer designs
- specify gapmer components
- introduce stereodefined gapmers
- define modified oligonucleotides
- describe LNA gapmer structure
- introduce mixed wing gapmer and gapbreaker oligonucleotides
- provide gapbreaker oligonucleotide design and formulae

### RNase H Activity and Recruitment

- define RNase H activity

### Efficacy

- determine efficacy of oligonucleotides

### Conjugate Moieties

- list conjugate moieties

### Stereodefined Oligonucleotides

- define stereodefined oligonucleotides

## Immunotoxicity Biomarker Assay:

- describe method for predicting immunotoxicity of oligonucleotides

## EXAMPLES

### Example 1

- isolate mouse hepatocytes and non-parenchymal cells
- culture and treat cells with oligonucleotides
- measure various biomarkers (LDH, albumin, GSH, ATP, cytokines)
- analyze mRNA and miRNA expression

### Example 2

- evaluate and validate predictive in vitro hepatotoxicity assays

### Example 3

- assess effect of oligonucleotides on hepatocyte function and cell viability

### Example 4

- measure ASO-mediated effect on apoptosis

### Example 5

- evaluate effect of oligonucleotides on hepatocyte-NPC co-cultures

### Example 6

- investigate changes in secreted cytokines and mir-122

### Example 7

- investigate miR122-release in hepatocyte-NPC co-cultures

### Example 8

- test ASOs in in vitro hepatotoxicity assay

### Example 9

- establish protocol for human primary hepatocytes

